172 related articles for article (PubMed ID: 14603040)
21. Immunotherapy for Head and Neck Squamous Cell Carcinoma.
Schoppy DW; Sunwoo JB
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1033-43. PubMed ID: 26568546
[TBL] [Abstract][Full Text] [Related]
22. Preservation of in vitro biological functions in regional lymph node lymphocytes in squamous head and neck cancer.
Saxon A; Portaro J
Cancer Res; 1977 Apr; 37(4):1159-64. PubMed ID: 139203
[TBL] [Abstract][Full Text] [Related]
23. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
24. [Effect of cisplatin alone or combined with monoclonal anti-programmed death ligand-1 antibody on lung adenocarcinoma cell line SPCA-1 and T lymphocytes].
Pan X; Xing Y; Shi M; Zhou T; Qian B; Chen Y
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jun; 37(6):416-20. PubMed ID: 25200040
[TBL] [Abstract][Full Text] [Related]
25. Combination nonviral interleukin 2 gene therapy and external-beam radiation therapy for head and neck cancer.
Bray D; Yu SZ; Koprowski H; Rhee J; Kumar S; Pericle F; Suntharalingam M; Van Echo DA; Li D; O'Malley BW
Arch Otolaryngol Head Neck Surg; 2003 Jun; 129(6):618-22. PubMed ID: 12810463
[TBL] [Abstract][Full Text] [Related]
26. Antibody-coated suture enhances immune response: important ideas emerge from multidisciplinary training.
Whiteside TL
Arch Otolaryngol Head Neck Surg; 1999 Nov; 125(11):1237-8. PubMed ID: 10555695
[No Abstract] [Full Text] [Related]
27. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-10 as a possible mediator of immunosuppressive effect in patients with squamous cell carcinoma of the head and neck.
Avradopoulos K; Mehta S; Blackinton D; Wanebo HJ
Ann Surg Oncol; 1997 Mar; 4(2):184-90. PubMed ID: 9084857
[TBL] [Abstract][Full Text] [Related]
29. Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma.
Katayama A; Ogino T; Bandoh N; Nonaka S; Harabuchi Y
Clin Cancer Res; 2005 Apr; 11(8):2937-46. PubMed ID: 15837745
[TBL] [Abstract][Full Text] [Related]
30. Functional and phenotypic analysis of lymphocytes in head and neck cancer.
Snyderman CH; Heo DS; Johnson JT; D'Amico F; Barnes L; Whiteside TL
Arch Otolaryngol Head Neck Surg; 1991 Aug; 117(8):899-905. PubMed ID: 1832546
[TBL] [Abstract][Full Text] [Related]
31. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
32. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
[TBL] [Abstract][Full Text] [Related]
33. Presence of membrane-bound TGF-beta1 and its regulation by IL-2-activated immune cell-derived IFN-gamma in head and neck squamous cell carcinoma cell lines.
Ahn YO; Lee JC; Sung MW; Heo DS
J Immunol; 2009 May; 182(10):6114-20. PubMed ID: 19414763
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of poor CD3 response in head and neck cancer.
Shibuya TY; Nugyen N; McLaren CE; Li KT; Wei WZ; Kim S; Yoo GH; Rogowski A; Ensley J; Sakr W
Clin Cancer Res; 2002 Mar; 8(3):745-51. PubMed ID: 11895904
[TBL] [Abstract][Full Text] [Related]
35. Generation of therapeutic T cells from draining lymph nodes in a murine model of head and neck squamous cell carcinoma.
Sadeghi N; Black MJ; Hier MP; Shenouda G; Karp SE
Arch Otolaryngol Head Neck Surg; 1997 Jan; 123(1):25-30. PubMed ID: 9006500
[TBL] [Abstract][Full Text] [Related]
36. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer.
Jebreel A; Mistry D; Loke D; Dunn G; Hough V; Oliver K; Stafford N; Greenman J
J Laryngol Otol; 2007 Mar; 121(3):246-52. PubMed ID: 17040593
[TBL] [Abstract][Full Text] [Related]
37. Hierarchical immunosuppression of regional lymph nodes in patients with head and neck squamous cell carcinoma.
Wang MB; Lichtenstein A; Mickel RA
Otolaryngol Head Neck Surg; 1991 Oct; 105(4):517-27. PubMed ID: 1762790
[TBL] [Abstract][Full Text] [Related]
38. Interleukins 2 and 12 activate natural killer cytolytic responses of peripheral blood mononuclear cells from patients with head and neck squamous cell carcinoma.
Rashleigh SP; Kusher DI; Endicott JN; Rossi AR; Djeu JY
Arch Otolaryngol Head Neck Surg; 1996 May; 122(5):541-7. PubMed ID: 8615973
[TBL] [Abstract][Full Text] [Related]
39. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
40. Induction of the intercellular adhesion molecule (ICAM-1) on squamous cell carcinoma by interferon gamma.
Scher RL; Koch WM; Richtsmeier WJ
Arch Otolaryngol Head Neck Surg; 1993 Apr; 119(4):432-8. PubMed ID: 8096142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
